Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab

British Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2001, Pages 577-582

  Graff, J ^a,e   Andries, D ^a   Elsner, M ^b   Westrup, D ^b   Bassus, S ^c   Franz, N ^c   Klinkhardt, U ^d   Harder, S ^d  

^a Biocenter Niederursel   (Germany)

^b Department of Cardiology ^*  (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Abciximab; P selectin; Platelet derived growth factor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; FIBRINOGEN; HEPARIN; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR AB;

ANTIGEN EXPRESSION; ARTICLE; BINDING KINETICS; BLOOD SAMPLING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DRUG INFUSION; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; MALE; PRIORITY JOURNAL; REDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET-DERIVED GROWTH FACTOR; TIME FACTORS;

EID: 0034832639     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.01392.x     Document Type: Article

References (31)

1. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
2. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER Study)
3. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery
4. Platelet alpha granule membrane protein that is associated with the plasma membrane after activation
5. Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine
6. Ticlopidine and ASA pretreatment reduces coagulation and platelet activation during coronary dilatation procedures
7. PTCA: Periprocedural platelet activation
8. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement
9. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728
10. Ex vivo-in vitro interaction between aspirin, clopidogrel and the GP IIb/IIIa-inhibitors abciximab and SR 121566A
11. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty
12. Quantitative investigations into the aggregation of blood platelets
13. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass
14. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry
15. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-β1 and platelet-derived growth factor AB
16. Pharmacodynamic study of F (abk) 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
17. Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents
18. Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid
19. Ticlopidine and platelet function in healthy volunteers
20. Signalling mechanisms in the regulation of vascular cell migration
21. PDGF ligand and receptor gene expression during repair of arterial injury
22. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes and granulocytes
23. Leukocyte crosstalk at the vascular wall
24. Antiplatelet effect of ticlopidine after coronary stenting
25. Platelet membrane activation markers are predictive for increased risk of acute ischaemic events after PTCA
26. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
27. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture
28. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selection but continue to circulate and function
29. A dual thrombin receptor system for platelet activation
30. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
31. High and moderate affinity pathways for α-thrombin induced platelet activation